Multiple myeloma is a type of cancer that affects plasma cells, which are white blood cell found in the bone marrow. Although it is incurable, there are a number of treatment options to help slow the progress of the disease and improve quality of life.
NICE has already recommended a number of treatment options for multiple myeloma – thalidomide, bortezomib and lenalidomide – which can greatly improve the length of time someone can live with the disease and their quality of life. This appraisal considers the use of pomalidomide, also known as Imnovid, for treating multiple myeloma after third or subsequent relapse.
Commenting on the guidance, Sir Andrew Dillon, NICE chief executive, said: “Unfortunately we cannot recommend pomalidomide as the analyses from Celgene, the company that markets the drug, showed that it does not offer enough benefit to justify its high price.”